Latest: Watch here for details of new products and services.
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
- Companies
- Company details
Abiogen Pharma
Pharmaceutical research, product lines, toll manufacturing
The company in detail
Profile
Research activity is the central heart, where all company
activities develop. Traditional studies on the osteo-articular
metabolism led to the marketing of four bisphosphonates and
established Abiogen Pharma as a unique world-wide
company.
Abiogen has recently developed studies in several other
fields, with particular interest in the central nervous
system and tumours.
In the field of anti-tumor agents, Abiogen is developing
new substances, using biotechnology and in cooperation
with international partners and American University
Research Centres.
In order to ensure international manufacturing standards,
Abiogen has designed and built a new production plant
which has been in operation since September 2001. The
new plant occupies a surface of about 100,000 square
metres, and is considered one of the most advanced in its
sector.
Out-licensing
New local approach in Osteoarthritis: INTRA-ARTICULAR CLODRONATE More
In-licensing
products in dermatology, diabetology , respiratory and muscle-skeletal More
R&D
To view this information, you must subscribe to Partneringtools.
Partnerships
To view this information, you must subscribe to Partneringtools.
Deals
To view this information, you must subscribe to Partneringtools.
Press Releases
(21st May 2008) Abiogen Pharma starts a clinical phase II in Panic Disorders with Abio 08/01. More
(20th Nov 2006) Abiogen starts a Phase II in cancer with its new cell-therapy. More
(1st Jul 2006) Pisa -- May, 2006 30th Abiogen Pharma today announced the start of a Phase II clinical trial in Vienna (Austria) in patients affected by GAD with ABIO 08/01, a new anti-anxiety drug. More
(20th Jun 2005) The license agreement grants Oryx the exclusive license to market the speciality Clasteon ® (the bisphosphonate Disodium Clodronate) in Canada. More
(14th Apr 2005) Pisa -- 14th April 2005 Abiogen Pharma today announced the start of a Phase I-II clinical trial in Italy using ABIO 05/01 cells for the treatment of peritoneal carcinosis More
(6th Apr 2004) A patented vaginal douche consisting of an aqueous solution to which gaseous substances are added (Medical Device). More
(8th Oct 2003) On 10th September 2003, the Committe for Orphan Medicinal Products (COMP) adopted a positive opinion on the designation of the product OGP (10-14)L as an orphan drug for the treatment of chronic idiopathic myelofibrosis (CIMF). More
(5th Dec 2002) The Italian Ministry of healt has authorized the experimentation of Abiogen Pharma's osteogenic growth peptide. More
(2nd Oct 2002) Dichloromethylene bisphosphonate (Cl2MBP), or clodronate, is a compound which can, potentially, counteract some pathogenetic factors of osteoarthritis. More
(26th Jun 2002) Abiogen Pharma SPA in its biotechnological compounds development program has committed to Philogen SRL a development programme to be concluded before April 2005 devoted to the research in Hepatitis C Virus (HCV) and Tetanic Toxin specific human immun More
(25th Jun 2002) The first drug Worldwide registered for the therapy of Osteogenesis Imperfecta is the fruit of Italian Pharmacological Research More
Senior management
To view this information, you must subscribe to Partneringtools.
Head office
Abiogen Pharma
via Meucci, 36
Ospedaletto
PI
56014
Italy
Tel: (39) 050 315 4349
Fax: (39) 050 3154351
www | email
via Meucci, 36
Ospedaletto
PI
56014
Italy
Tel: (39) 050 315 4349
Fax: (39) 050 3154351
www | email
Contact details
Mr Gabriele Scali
Licensing Business Development Manager
BD
Licensing Business Development Manager
BD
Company figures
Formed: 1997
Annual Turnover: €75123000,00 (2005)
Number of employees: 369
Annual Turnover: €75123000,00 (2005)
Number of employees: 369
Related categories
- Industry sector
- Biotech
- Pharmaceutical
- Biotechnology / Human therapeutics
- Medical device / Therapeutic device
- Pharmaceutical / Prescription
- Pharmaceutical / OTC/Non-Prescription
- Pharmaceutical / Generics
- Pharmaceutical / Personal Care
- Manufacturing
- Therapeutic target
- Blood and forming organs / Blood disorders / Blood disorders (other)
- Central Nervous System
- Central Nervous System / CNS (other)
- Central Nervous System / Pain / Pain, inflammatory
- Central Nervous System / Pain / Pain management general
- Dermatological
- Dermatological / Fungal infection
- Dermatological / Psoriasis
- Dermatological / Dermatological (other)
- Endocrinology / Sex hormone (other)
- Genito-urinary / Gender related medicine female / Gynecological disorder (other)
- Immune related disorders
- Immune related disorders / Immune disorder (non-specific)
- Immune related disorders / Immunostimulation
- Metabolism / Diabetes type I
- Metabolism / Mineral supplement
- Musculoskeletal
- Musculoskeletal / Musculoskeletal disorder (other)
- Musculoskeletal / Skeletal / Osteoporosis
- Musculoskeletal / Skeletal / Arthritis (non-specific)
- Musculoskeletal / Skeletal / Osteoarthritis
- Musculoskeletal / Skeletal / Rheumatoid arthritis
- Oncology
- Oncology / Tumor (other)
- Oncology / Cancer (other)
- Oncology / Cancer side effects / Chemotherapy side effects
- Oncology / Treatments / Chemotherapy
- Other therapeutic / Dietetic
- Respiratory / Rhinitis
- Respiratory / Throat disorder (other)
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us